JW Therapeutics 药明巨诺
Harry Lam is a seasoned professional in the biotechnology sector, currently serving as a Senior Technology Advisor at JW Therapeutics since July 2024. Lam is also the Founder and CEO of FAST Cell Therapy, Inc., a position held since February 2023. With previous roles including CTO and EVP Technical Operations at Acepodia and JW Therapeutics, as well as leadership positions at 23andMe, Affinita Biotech, Sanofi, Progenitor Cell Therapy, KaloBios, and Shire Regenerative Medicine, Lam has extensive experience in technical operations and manufacturing development. Academic credentials include a PhD in Chemical Engineering from Rensselaer Polytechnic Institute and a BSc in Chemical Engineering from the University of Birmingham.
This person is not in any teams
This person is not in any offices
JW Therapeutics 药明巨诺
JW Therapeutics is an innovative biotech company focusing on the latest clinical cell therapy technology. It is commited to the development, transformation and promotion of breakthrough cell-based immunotherapies to save the lives of cancer patients, improve their quality of life and bring new hope. JW Therapeutics was co-founded by WuXi AppTec, Juno Therapeutics in February 2016.